SignalXSignalX

XNCR Xencor Inc

Q3 2025 10-Q
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Xencor Inc Overview

Xencor Inc (XNCR) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk due to ongoing U.S. government shutdown since October 1, 2025, causing FDA and SEC furloughs, delaying regulatory reviews and capital access
  • • Material update on regulatory risk: IRA drug price negotiations now effective, with 10 drugs priced from January 1, 2026, and 15 more selected for 2025 negotiations
+3 more insights

Get deeper insights on Xencor Inc

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.